EUVIMEDEUVIMED entdecken
Crossref

Actionable Gene Alterations in Resected Non-Small Cell Lung Cancer: Primary Results From the AGA-R Study

Ilaria Attili, Gloria Pellizzari, Luca Bertolaccini, Carla Corvaja, Davide Vacirca, Mariano Lombardi, Gianluca Spitaleri, Pamela Trillo Aliaga, Ester Del Signore, Antonio Passaro, Juliana Guarize, Elena Guerini-Rocco und 3 weitere

Clinical Lung Cancer · 2026

DOI: 10.1016/j.cllc.2025.09.015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lung Cancer, 2026. Verfasst von Ilaria Attili und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy. Electronic address: Ilaria.attili@ieo.it. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Mutation, Biomarkers, Tumor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: In resected non-small cell lung cancer (NSCLC), molecular testing is currently limited to EGFR mutations and ALK rearrangements, as these guide approved adjuvant therapies. The role of next-generation sequencing (NGS), routinely used in metastatic NSCLC, remains unclear in earlier stages. The prevalence of other driver mutations and their impact on outcomes is not well established. METHODS: We retrospectively analyzed clinical, molecular, and survival data from patients (pts) with stage IA-IIIB NSCLC (AJCC 8th) who underwent surgery and NGS at our Institute from January 2020 to December 2023. The primary endpoint was the prevalence of driver alterations. Exploratory analyses assessed recurrence, disease-free survival (DFS), overall survival (OS), and correlation with mutation status. RESULTS: Of 221 pts, 216 were eligible. Oncogenic alterations were found in 71% (73% in stage I), most commonly KRAS (30%) and EGFR (26%), followed by MET exon 14 skipping (6%), BRAF (4%), HER2 exon 20 mutations (3%), and ALK and RET rearrangements (1%). Alteration distribution differed by sex and smoking status. With a median follow-up of 20 months, 36% of pts experienced recurrence, including 10 stage I cases. Median time to recurrence was 14 months. Recurrence rates were higher in pts with driver mutant NSCLC (39.6%) versus wild-type (29.6%). Highest recurrence was seen in pts with oncogenic fusion positive NSCLC and EGFR exon 20 insertions. CONCLUSIONS: Driver mutations were detected in 70% of resected NSCLC, including stage I. The recurrence patterns observed support integrating NGS into early-stage management and exploring tailored adjuvant therapies, even for stage I tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsMutationBiomarkers, TumorHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultHigh-Throughput Nucleotide SequencingErbB ReceptorsAged, 80 and overFollow-Up StudiesPrognosisSurvival RateAnaplastic Lymphoma Kinase

Stichwörter der Autor:innen

NGSdriver genesrecurrenceresected NSCLCsurgery

Substanzen

ErbB ReceptorsBiomarkers, TumorEGFR protein, humanAnaplastic Lymphoma Kinase

Autor:innen und Institutionen

  • Division of Thoracic Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy. Electronic address: Ilaria.attili@ieo.it.
  • Department of Oncology and Haemato-Oncology, University of Milan, Milan, Italy.
  • Division of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Division of Thoracic Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Division of Pathology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Division of Interventional Pulmonology, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Förderung

  • Ministry of Health

Zitieren

APA

Attili, I., Pellizzari, G., Bertolaccini, L., Corvaja, C., Vacirca, D., Lombardi, M., Spitaleri, G., Trillo Aliaga, P., Del Signore, E., Passaro, A., Guarize, J., Guerini-Rocco, E., Fusco, N., Spaggiari, L., & de Marinis, F. (2026). Actionable Gene Alterations in Resected Non-Small Cell Lung Cancer: Primary Results From the AGA-R Study. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2025.09.015

Vancouver

Attili I, Pellizzari G, Bertolaccini L, Corvaja C, Vacirca D, Lombardi M, et al. Actionable Gene Alterations in Resected Non-Small Cell Lung Cancer: Primary Results From the AGA-R Study. Clinical Lung Cancer. 2026. doi:10.1016/j.cllc.2025.09.015

BibTeX
@article{Attili2026,
  author = {Attili, Ilaria and Pellizzari, Gloria and Bertolaccini, Luca and Corvaja, Carla and Vacirca, Davide and Lombardi, Mariano and Spitaleri, Gianluca and Trillo Aliaga, Pamela and Del Signore, Ester and Passaro, Antonio and Guarize, Juliana and Guerini-Rocco, Elena and Fusco, Nicola and Spaggiari, Lorenzo and de Marinis, Filippo},
  title = {Actionable Gene Alterations in Resected Non-Small Cell Lung Cancer: Primary Results From the AGA-R Study},
  journal = {Clinical Lung Cancer},
  year = {2026},
  doi = {10.1016/j.cllc.2025.09.015}
}
Kostenlos starten →